Skip to main content

Addiction to Benzodiazepines

Abstract

Benzodiazepines are sedative hypnotic medications that can induce a state of dependence. Dependence however is not the same as addiction. The development of dependence is a predictable phenomenon, influenced by dose, duration of treatment, and a number of other factors including individual characteristics of the benzodiazepine user. It is unclear whether there are meaningful differences among benzodiazepines in producing a state of dependence. Benzodiazepine dependence is also characterized by a predictable discontinuation syndrome. Benzodiazepines are rarely abused by non-substance abusers. The regulation of benzodiazepines although the legitimate therapeutic use has been significantly reduced.

This is a preview of subscription content, access via your institution.

REFERENCES

  1. 1.

    Salzman C: Issues and controversies regarding benzodiazepine use. NIDA Research Monograph Series 131:68-89, 1993.

  2. 2.

    Salzman C: Benzodiazepine treatment of panic and agoraphobic symptoms: use, dependence, toxicity, abuse. Journal of Psychiatric research 27:97-110, 1993.

    PubMed  Google Scholar 

  3. 3.

    Salzman C, Watsky E: Rational prescribing of benzodiazepines, in Benzodiazepine Dependence. Edited by Hallström C. Oxford, Oxford University Press, pp 13-33, 1993.

    Google Scholar 

  4. 4.

    Salzman C: The benzodiazepine controversy: therapeutic effects versus dependence, withdrawal and toxicity. Harvard Review of Psychiatry. In Press.

  5. 5.

    Salzman C, Freeman S: Benefits versus risks of benzodiazepine. Psychiatric annals. In Press.

  6. 6.

    Woods JH, Winger G: Current benzodiazepine issues. Psychopharmacology 118: 107-115, 1995.

    PubMed  Google Scholar 

  7. 7.

    Woods JH, Katz JL, Winger G: Benzodiazepines: use, abuse, and consequences. Pharmacology Review 44:151-347. 1992.

    Google Scholar 

  8. 8.

    American Psychiatric Association Task Force Report on Benzodiazepine Dependence, Toxicity, and Abuse 1990; Washington, American Psychiatric Press.

  9. 9.

    Stephens DN, and Turski L: Adaptive changes to chronic treatment with ligands for benzodiazepine receptors: inverse agonists and tolerance to agonists, in Benzodiazepine Receptor Inverse Agonists. Edited by Sarter M, Nutt DJ, Lister RG. New York: Wiley-Liss, pp 83-112, 1995.

    Google Scholar 

  10. 10.

    Shader RI, Greenblatt DJ: Use of benzodiazepines in anxiety disorders. New England Journal of Medicine 328:1398-1405, 1993.

    PubMed  Google Scholar 

  11. 11.

    Balter MB, Uhlenhuth EH: New epidemiologic findings about insomnia and its treatment. Journal of Clinical Psychiatry 53[12 Suppl]:34-39, 1992.

    PubMed  Google Scholar 

  12. 12.

    Balter MB, Ban TA, Uhlenhuth EH: International study of expert judgement on therapeutic use of benzodiazepines and other psychotherapeutic medications: I. Current concerns. Human Psychopharmacology 8:253-261, 1993.

    Google Scholar 

  13. 13.

    Mellinger GD, Balter MB, Uhlenhuth EH: Prevalence and correlates of the long-term regular use of anxiolytics. Journal of the American Medical Association 251:375-379, 1984.

    PubMed  Google Scholar 

  14. 14.

    Johnston LD, O'Malley PM, Bachman JG: National survey results on drug use from monitoring the future study, 1975–1992. NIDA, NIH Publication No. 93-3597. USDHHS, US Government Printing Office Washington, D.C., 1993.

  15. 15.

    Fernandez F, Levy JK: Use of benzodiazepines in the medically ill, in Benzodiazepines in Clinical Practice: Risks and Benefits. Edited by PP Roy-Byrne. Washington: American Psychiatric Press, pp 177-200, 1991.

    Google Scholar 

  16. 16.

    Ciraulo DA, Sarid-Segal O: Benzodiazepines: abuse liability, in Benzodiazepines in Clinical Practice: Risks and Benefits. Edited by Roy-Byrne PP and Cowley DS. Washington, DC: American Psychiatric Press, pp 157-174, 1991.

    Google Scholar 

  17. 17.

    Griffiths RR, Weerts EM: Benzodiazepine self-administration in humans and laboratory animals—implications for problems of long-term use and abuse. Psychopharmacology, 134:1-37, 1997.

    PubMed  Google Scholar 

  18. 18.

    King MB, Gabe J, Williams P, Rodrigo EK: Long term use of benzodiazepines: the views of patients. British Journal of General Practice 40:194-196, 1990.

    PubMed  Google Scholar 

  19. 19.

    Griffiths RR: Commentary on review by Woods and Winger. Benzodiazepines: long-term use among patients is a concern and abuse among polydrug abusers is not trivial. Psychopharmacology, 118:116-117, 1995.

    PubMed  Google Scholar 

  20. 20.

    Busto UE, Romach MK, Sellers EM: Multiple drug use and psychiatric comorbidity in patients admitted to the hospital with Psychopharmacology 16:51-57, 1996.

    Google Scholar 

  21. 21.

    Barnas C, Rossmann M, Roessler H et al: Benzodiazepines and other psychotropic drugs abused by patients in a methadone maintenance program: familiarity and preference. Journal of Clinical Psychopharmacology 12:397-402, 1992.

    PubMed  Google Scholar 

  22. 22.

    Griffith RR, Wolf B: Relative abuse liability of different benzodiazepines in drug abusers. Journal of Clinical Psychopharmacology 10[4]:237-243, 1990.

    PubMed  Google Scholar 

  23. 23.

    Iguchi MY, Handelsman L, Bickel WK, Griffiths RR: Benzodiazepine and sedative use/abuse by methadone maintenance clients. Drug and Alcohol Dependence 32:257-266, 1993.

    PubMed  Google Scholar 

  24. 24.

    Darke SG, Ross JE, Hall WD: Benzodiazepine use among injecting heroin users. Medical Journal of Australia 162:645-647, 1995.

    PubMed  Google Scholar 

  25. 25.

    Shader RI, Greenblatt DJ, Balter MB: Appropriate use and regulatory control of benzodiazepines. Journal of Clinical Pharmacology 31: 781-784, 1991.

    PubMed  Google Scholar 

  26. 26.

    Schwartz HI, Blank K: Regulation of benzodiazepine prescribing practices: clinical implications. General Hospital Psychiatry 13:219-224, 1991.

    PubMed  Google Scholar 

  27. 27.

    Reidenberg MM: Effect of the requirement for triplicate prescriptions for benzodiazepines in New York State. Clinical Pharmacol Therapeutics 50:129-131, 1991.

    Google Scholar 

  28. 28.

    Hoffman RS, Wipfler JG, Maddaloni MA, et al: Has the New York State triplicate benzodiazepine prescription regulation influenced sedative-hypnotic overdoses? New York State Journal of Medicine 91:436-439, 1991.

    PubMed  Google Scholar 

Download references

Author information

Affiliations

Authors

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Salzman, C. Addiction to Benzodiazepines. Psychiatr Q 69, 251–261 (1998). https://doi.org/10.1023/A:1022125929946

Download citation

Keywords

  • Public Health
  • Individual Characteristic
  • Meaningful Difference
  • Discontinuation Syndrome
  • Hypnotic Medication